{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:56Z","timestamp":1788474776899,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Czech Pulmonological and Phthisiological Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO<jats:sub>2peak<\/jats:sub>) is an appropriate tool to evaluate the physical activity in these patients. However, there are several other valuable CPET parameters describing exercise tolerance (W<jats:sub>peak<\/jats:sub>, VO<jats:sub>2VT1<\/jats:sub>, VO<jats:sub>2VT2,<\/jats:sub> VO<jats:sub>2<\/jats:sub>\/HR<jats:sub>peak<\/jats:sub>, etc.), and helping to better understand the effect of specific treatment (V<jats:sub>E<\/jats:sub>, V<jats:sub>T<\/jats:sub>, V<jats:sub>D<\/jats:sub>\/V<jats:sub>T<\/jats:sub> etc.). Limited data showed ambiguous results of this improvement after CFTR modulator treatment. Elexacaftor\/tezacaftor\/ivacaftor medication improves pulmonary function and quality of life, whereas its effect on CPET has yet to be sufficiently demonstrated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a single group prospective observational study of 10 adolescent patients with cystic fibrosis who completed two CPET measurements between January 2019 and February 2023. During this period, elexacaftor\/tezacaftor\/ivacaftor treatment was initiated in all of them. The first CPET at the baseline was followed by controlled CPET at least one year after medication commencement. We focused on interpreting the data on their influence by the novel therapy. We hypothesized improvements in cardiorespiratory fitness following treatment. We applied the Wilcoxon signed-rank test. The data were adjusted for age at the time of CPET to eliminate bias of aging in adolescent patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed significant improvement in peak workload, VO<jats:sub>2 peak<\/jats:sub>, VO<jats:sub>2VT1<\/jats:sub>, VO<jats:sub>2VT2<\/jats:sub>, V<jats:sub>E<\/jats:sub>\/VCO<jats:sub>2<\/jats:sub> slope, V<jats:sub>E<\/jats:sub>, V<jats:sub>T<\/jats:sub>, RQ, VO<jats:sub>2<\/jats:sub>\/HR\u00a0peak and RR\u00a0peak. The mean change in VO<jats:sub>2\u00a0<\/jats:sub>peak\u00a0was 5.7\u00a0mL\/kg\/min, or 15.9% of the reference value (SD\u2009\u00b1\u200916.6;\u00a0<jats:italic>p<\/jats:italic>=\u20090.014). VO<jats:sub>2VT1<\/jats:sub> improved by 15% of the reference value (SD\u2009\u00b1\u20090.1;\u00a0<jats:italic>p<\/jats:italic>=\u20090.014), VO<jats:sub>2VT2\u00a0<\/jats:sub>improved by 0.5 (SD\u2009\u00b1\u20090.4;\u00a0<jats:italic>p<\/jats:italic>=\u20090.01). There were no differences in other parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Exercise tolerance improved after elexacaftor\/tezacaftor\/ivacaftor treatment initiation. We suggest that the CFTR modulator alone is not enough for recovering physical decondition, but should be supplemented with physical activity and respiratory physiotherapy. Further studies are needed to examine the effect of CFTR modulators and physical therapy on cardiopulmonary exercise tolerance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-03069-8","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T17:30:03Z","timestamp":1716917403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The long-term effect of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study"],"prefix":"10.1186","volume":"24","author":[{"given":"Nela","family":"Stastna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Hrabovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Homolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Homola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Brat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Fila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"2","key":"3069_CR1","first-page":"217","volume":"126","author":"FJ Cerny","year":"1982","unstructured":"Cerny FJ, Pullano TP, Cropp GJ. Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis. 1982;126(2):217\u201320.","journal-title":"Am Rev Respir Dis"},{"issue":"11","key":"3069_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.rmed.2004.03.016","volume":"98","author":"AG Thin","year":"2004","unstructured":"Thin AG, Dodd JD, Gallagher CG, Fitzgerald MX, Mcloughlin P. Effect of respiratory rate on airway deadspace ventilation during exercise in cystic fibrosis. Respir Med. 2004;98(11):1063\u201370.","journal-title":"Respir Med"},{"issue":"5","key":"3069_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.154.5.8912758","volume":"154","author":"JA Regnis","year":"1996","unstructured":"Regnis JA, Donnelly PM, Robinson M, Alison JA, Bye PT. Ventilatory mechanics at rest and during exercise in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1418\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3069_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0022-3476(96)70067-7","volume":"129","author":"PA Nixon","year":"1996","unstructured":"Nixon PA, Joswiak ML, Fricker FJ. A six-minute walk test for assessing exercise tolerance in severely ill children. J Pediatr. 1996;129(3):362\u20136.","journal-title":"J Pediatr"},{"key":"3069_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2466-14-74","volume":"14","author":"J Pastr\u00e9","year":"2014","unstructured":"Pastr\u00e9 J, Pr\u00e9votat A, Tardif C, Langlois C, Duhamel A, Wallaert B. Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med. 2014;14:74.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"3069_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1164\/ajrccm.153.3.8630552","volume":"153","author":"P Pianosi","year":"1996","unstructured":"Pianosi P, Pelech A. Stroke volume during exercise in cystic fibrosis. Am J Respir Crit Care Med. 1996;153(3):1105\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3069_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1445-5994.2009.02039.x","volume":"41","author":"I Szollosi","year":"2011","unstructured":"Szollosi I, King SJ, Wilson JW, Naughton MT. Tachycardia in adults with cystic fibrosis is associated with normal autonomic function. Intern Med J. 2011;41(6):455\u201361.","journal-title":"Intern Med J"},{"issue":"8","key":"3069_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1164\/rccm.201806-1110OC","volume":"199","author":"H Hebestreit","year":"2019","unstructured":"Hebestreit H, Hulzebos EHJ, Schneiderman JE, Karila C, Boas SR, Kriemler S, et al. Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis. Am J Respir Crit Care Med. 2019;199(8):987\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"3069_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1042\/CS20170995","volume":"131","author":"D Edgeworth","year":"2017","unstructured":"Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, et al. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clin Sci (Lond). 2017;131(15):2037\u201345.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"3069_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jcf.2020.12.006","volume":"20","author":"J Wilson","year":"2021","unstructured":"Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, et al. VO2max as an exercise tolerance endpoint in people with cystic fibrosis: lessons from a lumacaftor\/ivacaftor trial. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20(3):499\u2013505.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"4","key":"3069_CR11","first-page":"454","volume":"26","author":"ZL Saynor","year":"2014","unstructured":"Saynor ZL, Barker AR, Oades PJ, Williams CA. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. Pediatr Phys Ther Off Publ Sect Pediatr Am Phys Ther Assoc. 2014;26(4):454\u201361.","journal-title":"Pediatr Phys Ther Off Publ Sect Pediatr Am Phys Ther Assoc"},{"issue":"3","key":"3069_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jcf.2019.03.001","volume":"18","author":"D Savi","year":"2019","unstructured":"Savi D, Schiavetto S, Simmonds NJ, Righelli D, Palange P. Effects of Lumacaftor\/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2019;18(3):420\u20134.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"3069_CR13","doi-asserted-by":"crossref","unstructured":"Ahmed MI, Dayman N, Madge J, Gaillard E. P91 Cardiopulmonary exercise testing in CF adolescents after starting Tezacaftor\/Ivacaftor. Thorax. 2021;76(Suppl 1):A136\u2013A136.","DOI":"10.1136\/thorax-2020-BTSabstracts.236"},{"issue":"19","key":"3069_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"key":"3069_CR15","doi-asserted-by":"publisher","unstructured":"Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians\u2019 views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;0(0). https:\/\/doi.org\/10.1016\/j.jcf.2023.03.011.","DOI":"10.1016\/j.jcf.2023.03.011"},{"issue":"11","key":"3069_CR16","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/ppul.26078","volume":"57","author":"AJ Causer","year":"2022","unstructured":"Causer AJ, Shute JK, Cummings MH, Shepherd AI, Wallbanks SR, Pulsford RM, et al. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatr Pulmonol. 2022;57(11):2652\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"3069_CR17","first-page":"332","volume":"90","author":"H Hebestreit","year":"2015","unstructured":"Hebestreit H, Arets HGM, Aurora P, Boas S, Cerny F, Hulzebos EHJ, et al. Statement on exercise testing in cystic fibrosis. Respir Int Rev Thorac Dis. 2015;90(4):332\u201351.","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"5","key":"3069_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","volume":"21","author":"UK Rysgaard","year":"2022","unstructured":"Rysgaard UK, Pedersen CL, Jensen JH, S\u00f8rensen L, Philipsen LKD, Leo-Hansen C, et al. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(5):844\u20139.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"2","key":"3069_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2021.11.011","volume":"21","author":"JE Caterini","year":"2022","unstructured":"Caterini JE, Ratjen F, Barker AR, Williams CA, Rendall K, Schneiderman JE, et al. Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(2):282\u201392.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"4","key":"3069_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0008-6363(95)00245-6","volume":"31","author":"JD Warth","year":"1996","unstructured":"Warth JD, Collier ML, Hart P, Geary Y, Gelband CH, Chapman T, et al. CFTR chloride channels in human and simian heart. Cardiovasc Res. 1996;31(4):615\u201324.","journal-title":"Cardiovasc Res"},{"issue":"Pt 2","key":"3069_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1113\/jphysiol.2005.085019","volume":"568","author":"R Robert","year":"2005","unstructured":"Robert R, Norez C, Becq F. Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells. J Physiol. 2005;568(Pt 2):483\u201395.","journal-title":"J Physiol"},{"issue":"6","key":"3069_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.21982","volume":"67","author":"AM Lamhonwah","year":"2010","unstructured":"Lamhonwah AM, Bear CE, Huan LJ, Kim Chiaw P, Ackerley CA, Tein I. Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise. Ann Neurol. 2010;67(6):802\u20138.","journal-title":"Ann Neurol"},{"key":"3069_CR23","doi-asserted-by":"crossref","unstructured":"Malik FA, Meissner A, Semenkov I, Molinski S, Pasyk S, Ahmadi S, et al. Sphingosine-1-phosphate is a novel regulator of cystic fibrosis transmembrane conductance regulator (CFTR) activity. PLoS One . 2015;10(6):e0130313.","DOI":"10.1371\/journal.pone.0130313"},{"key":"3069_CR24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3389\/fphys.2018.01585","volume":"9","author":"T Mad\u00e1csy","year":"2018","unstructured":"Mad\u00e1csy T, Pallagi P, Maleth J. Cystic fibrosis of the pancreas: the role of CFTR channel in the regulation of intracellular Ca2+ signaling and mitochondrial function in the exocrine pancreas. Front Physiol. 2018;9:1585.","journal-title":"Front Physiol"},{"issue":"5","key":"3069_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1165\/rcmb.2005-0473OC","volume":"35","author":"LW Velsor","year":"2006","unstructured":"Velsor LW, Kariya C, Kachadourian R, Day BJ. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol. 2006;35(5):579\u201386.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"3069_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1183\/09031936.00086211","volume":"39","author":"PB van de Weert-van Leeuwen","year":"2012","unstructured":"van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CLJJ, van der Ent CK, Arets HGM. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J. 2012;39(4):893\u20138.","journal-title":"Eur Respir J"},{"issue":"8","key":"3069_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey M, Gabillard-Lefort C, McElvaney OF, McElvaney OJ, Carroll T, Heeney RC, et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023;78(8):835\u20139.","journal-title":"Thorax"},{"issue":"7","key":"3069_CR28","doi-asserted-by":"publisher","first-page":"e1000586","DOI":"10.1371\/journal.pgen.1000586","volume":"5","author":"M Divangahi","year":"2009","unstructured":"Divangahi M, Balghi H, Danialou G, Comtois AS, Demoule A, Ernest S, et al. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 2009;5(7):e1000586.","journal-title":"PLoS Genet"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03069-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T17:30:15Z","timestamp":1716917415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03069-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03069-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by University Hospital Brno committee.Informed consent was obtained from all subject or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}